Idarubicine plus methotrexate improves outcome of patients primary central nervous system lymphoma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015137

Enrollment

Unknown

Registered

2018-03-10

Start date

2018-04-01

Completion date

Unknown

Last updated

2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

Case:IDA Plus MTX

Control:MTX only

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18-65 diagnosed with primary central nervous lymphoma.

Exclusion criteria

Exclusion criteria: Pregnant, without primary central nervous lymphoma,

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactBobin Chen

Huashan Hospital, Fudan University

bbchen@fudan.edu.cn+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026